KDM2B and glioblastoma: In addition, both siRNA‐mediated KDM2B loss as well as chemical inhibition using GSK‐J4 significantly sensitized tumor cells to chemotherapeutics used in clinical management of glioblastoma (Taal et al., 2014; Wick et al., 2017): lomustine and etoposide.